Dr. Zhenyang Liu 刘振洋
Chief Physician
Department of Medical Oncology, Hunan Cancer Hospital, Changsha
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy, targeted therapy, and integrated traditional Chinese and Western medicine for colorectal, gastric, lung, breast, lymphoma, prostate, kidney, bladder, esophageal, and nasopharyngeal cancers.
Dr. Liu is Chief Physician and Deputy Director of the Digestive and Urological Internal Medicine Department. Holding a medical doctorate from Central South University, Dr. Liu completed postdoctoral research at Massachusetts General Hospital, Harvard Medical School. After starting in the Traditional Chinese Medicine department, Dr. Liu moved to internal medicine, focusing on chemotherapy, targeted therapy, and integrated traditional Chinese and Western medicine.
Name order: in Chinese the family name comes first (Liu Zhenyang). Papers usually list the name as Zhenyang Liu or Liu Z.
Selected publications
19 papers on PubMed matched by name and affiliation; 6 as first or senior author since 2016. Most recent first- or senior-author papers:
- Int J Cancer, 2026 (senior author): Fruquintinib with programmed cell death - 1 inhibitors versus triflueridine - tipiracil - 102 with bevacizumab in late-line mCRC: A retrospective cohort study based on propensity score matching. PubMed 41684147
- J Gastrointest Oncol, 2024 (senior author): Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: a retrospective cohort study. PubMed 38756644
- Am J Transl Res, 2023 (senior author): Correlation analysis of the expression of mesenchymal circulating tumor cells and CD133 with the prognosis of colorectal cancer. PubMed 37303671
- Pharm Biol, 2022 (senior author): A novobiocin derivative, XN4, triggers ferroptosis in gastric cancer cells via the activation of NOX4. PubMed 35938505
- Ann Transl Med, 2022 (senior author): Efficacy and safety of anti-PD-1 antibody plus regorafenib in refractory microsatellite stable metastatic colorectal cancer: a retrospective single-arm cohort study. PubMed 36111036
- J Transl Med, 2020 (first author): A fast, simple, and cost-effective method of expanding patient-derived xenograft mouse models of pancreatic ductal adenocarcinoma. PubMed 32580742
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion